Distinct Metastatic Phenotypes Between Early-onset and Late-onset Colorectal Cancer

Completed

• Conditions: Late-onset Colorectal Cancer; Early-onset Colorectal Cancer

• Registration Number: NCT06040021
• Lead Sponsor: Fudan University

Brief Summary

The clinical and pathological features of early-onset colorectal cancer (EOCRC) differ from those of late-onset colorectal cancer (LOCRC). Our research aims to thoroughly elucidate the distinctions between them by analyzing clinical prognosis, metastatic patterns, gene expression, and genomic mutation profiles. Our deliberation will uncover latent strategies for personalized therapeutic of both EOCRC and LOCRC.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01-01
• Primary Completion: 2018-12-31
• Study Completion: 2023-06-30
• Status Verified: 2023-09
• Study First Submitted: 2023-09-11
• Study First Submitted QC: 2023-09-11
• Last Update Submitted: 2023-09-11
• Study First Posted: 2023-09-15
• Last Update Posted: 2023-09-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15244

Inclusion Criteria

• The initial diagnosis of colonoscopy and pathology belongs to colorectal cancer;
• Patients should sign an informed consent form after fully understanding the purpose, procedures and potential risks of the study, indicating their voluntary participation in the research.

Exclusion Criteria

• Patients with obvious local or systemic severe infection;
• Acute abdomen: intestinal obstruction, peritonitis, intestinal perforation;
• Have a systemic underlying disease that has not been controlled, or is unstable;
• Patients with poor physical fitness or serious other organic diseases who cannot tolerate anesthesia and surgery;
• Women during pregnancy, perinatal and lactation;
• Patients with severe mental disorders (such as schizophrenia, bipolar disorder, etc.) or patients who are mentally incapable or unable to understand the requirements for participation in the study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
OS	5 years after intervention	overall survival